Literature DB >> 27849377

IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM.

Poupak Fallahi, Silvia Martina Ferrari, Alessandro Antonelli.   

Abstract

OBJECTIVE: Levothyroxine (L-T4) is the standard therapy of hypothyroidism. Our purpose was to compare the effectiveness of the L-T4 liquid formulation with respect to L-T4 tablet in hypothyroid patients without malabsorption or drug interference. Twenty-one subjects with high thyroid-stimulating hormone (TSH) values under therapy with L-T4 tablets were switched to liquid L-T4 at the same dosage given 30 minutes before breakfast.
RESULTS: TSH values significantly declined 2 months after from the switch to liquid L-T4, reaching the normal range in most cases. In 15 (of the 21 patients) who switched back to tablets, TSH increased again to the hypothyroid range. Since the liquid L-T4 formulation resulted in better TSH level control, all patients were finally treated with the liquid L-T4, and TSH, free tri-iodothyronine and free thyroxine were evaluated again after 6 and 12 months, resulting in normal ranges in all subjects.
CONCLUSIONS: The change from tablets to liquid oral formulation normalized serum TSH levels, while switching back to tablets caused thyrotropin levels to worsen. These results suggest that the liquid L-T4 formulation is more effective than tablets in controlling TSH levels in hypothyroid patients in the absence of malabsorption, gastric disorders, or drug interference. ABBREVIATIONS: BMI = body mass index FT3 = free tri-iodothyronine FT4 = free thyroxine L-T4 = levothyroxine PPIs = proton-pump inhibitors TSH = thyroid-stimulating hormone.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27849377     DOI: 10.4158/EP161545.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  19 in total

Review 1.  Novel thyroxine formulations: a further step toward precision medicine.

Authors:  Camilla Virili; Pierpaolo Trimboli; Marco Centanni
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

2.  Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015.

Authors:  Rosarita Ferrara; Valentina Ientile; Vincenzo Arcoraci; Carmen Ferrajolo; Carlo Piccinni; Andrea Fontana; Salvatore Benvenga; Gianluca Trifirò
Journal:  Endocrine       Date:  2017-02-02       Impact factor: 3.633

3.  Treatment of refractory and severe hypothyroidism with sublingual levothyroxine in liquid formulation.

Authors:  Carmela Peirce; Serena Ippolito; Alejandra Lanas; Marcella Pesce; Gilda Pontieri; Debora Arpaia; Giovanni Sarnelli; Bernadette Biondi
Journal:  Endocrine       Date:  2017-07-13       Impact factor: 3.633

Review 4.  Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis.

Authors:  Irakoze Laurent; Siying Tang; Manirakiza Astère; Kan Ran Wang; Shuhua Deng; Ling Xiao; Qi Fu Li
Journal:  Endocrine       Date:  2018-03-23       Impact factor: 3.633

5.  Therapeutic Equivalence of a New Preparation of Liquid Levothyroxine with Tablets in Patients with Overt Primary Hypothyroidism.

Authors:  Georgios K Markantes; Konstantinos Dimitropoulos; Irene Mamali; Ioulia Tseti; George Sakellaropoulos; Kostas B Markou; Marina A Michalaki
Journal:  Eur Thyroid J       Date:  2020-06-23

6.  Drug interactions in users of tablet vs. oral liquid levothyroxine formulations: a real-world evidence study in primary care.

Authors:  Valeria Guglielmi; Alfonso Bellia; Elisa Bianchini; Gerardo Medea; Iacopo Cricelli; Paolo Sbraccia; Davide Lauro; Claudio Cricelli; Francesco Lapi
Journal:  Endocrine       Date:  2017-09-14       Impact factor: 3.633

7.  Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis.

Authors:  Camilla Virili; Luca Giovanella; Poupak Fallahi; Alessandro Antonelli; Maria Giulia Santaguida; Marco Centanni; Pierpaolo Trimboli
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-26       Impact factor: 5.555

8.  l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism.

Authors:  Salvatore Benvenga; Giovanni Capodicasa; Sarah Perelli
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-20       Impact factor: 5.555

9.  Severe Hypothyroidism due to the Loss of Therapeutic Efficacy of l-Thyroxine in a Patient with Esophageal Complication Associated with Systemic Sclerosis.

Authors:  Antonio Lobasso; Liliana Nappi; Letizia Barbieri; Carmela Peirce; Serena Ippolito; Debora Arpaia; Francesca Wanda Rossi; Amato de Paulis; Bernadette Biondi
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-20       Impact factor: 5.555

10.  Thyroxine Treatment With Softgel Capsule Formulation: Usefulness in Hypothyroid Patients Without Malabsorption.

Authors:  Pierpaolo Trimboli; Camilla Virili; Marco Centanni; Luca Giovanella
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.